Safety and Efficacy of Subcutaneous Daratumumab in Systemic AL Amyloidosis

Hughes, M., & Lentzsch, S. (2023). Safety and Efficacy of Subcutaneous Daratumumab in Systemic AL Amyloidosis. Therapeutics and Clinical Risk Management, Volume 19, 1063–1074. https://doi.org/10.2147/tcrm.s325859
Authors:
Michael Sang Hughes
Suzanne Lentzsch
Affiliated Authors:
Michael Sang Hughes
Suzanne Lentzsch
Columbia Affiliation:
Subjects:
Molecular Mechanisms of Amyloidosis (OpenAlex Topic)
Molecular Pathogenesis of Myeloproliferative Disorders (OpenAlex Topic)
Hypereosinophilic Syndrome and Related Disorders (OpenAlex Topic)
Author Keywords:
plasma cell dyscrasia
daratumumab
al amyloidosis
adverse events
ae
elink
Publication Type:
Article
Unique ID:
10.2147/tcrm.s325859
PMID:
38164204
DOI:
10.2147/tcrm.s325859
Journal:
Therapeutics and Clinical Risk Management
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record
View PubMed Record
View Web of Science Record

Record Created: